https://www.sec.gov/ix?doc=/Archives/edgar/data/0000105770/000010577026000093/wst-20260714.htm

The terms of the Agreements are substantially similar to the terms of the Amended and Restated Technology Exchange and Crosslicense Agreement dated January 18, 2017 and the two Distributorship Agreements dated January 18, 2017 between the parties, as amended by the Letter Agreement dated July 2, 2018 and the Amendment Agreement dated October 15, 2019.

Under the Crosslicense Agreement, each party has agreed to share with the other its know-how relating to, and to cooperate in the joint development of, closures, vials, cartridges, syringes, medical device components and similar products used in connection with the packaging, delivery, administration or dispensing of pharmaceutical products. The Crosslicense Agreement permits each party to license the other’s know-how, patents and trademarks in the manufacture, use and sale of those products. Daikyo’s license from West is non-exclusive and West’s license from Daikyo is exclusive outside of Japan subject to certain limited exceptions. The Crosslicense Agreement is royalty-free except for a fixed royalty rate that is generally applicable to the licensing of certain patents and non-patented technical information.

One Distributorship Agreement authorizes the Company as the exclusive distributor of Daikyo products in all countries other than Japan, subject to certain limited exceptions. The other Distributorship Agreement authorizes Daikyo as a non-exclusive distributor of Company products in Japan. Both Distributorship Agreements are otherwise substantially similar in material terms and conditions.

Each of the Agreements has a 10-year term. Each Agreement may be terminated before its respective term expires under certain circumstances, including, but not limited to, mutual written consent or in the event of a change in control of either party. If the Crosslicense Agreement is terminated, the parties have agreed to negotiate within a specified period the terms under which they may continue to use the know-how and trademarks and to make, use or sell products under licensed patents.

The foregoing descriptions of each of the Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of each of the Agreements, redacted copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending on September 30, 2026.